Company Name: M1 Kliniken AG ISIN: DE000A0STSQ8   Reason for the research: Jahresbericht 2024 und Q1/25 KPIs Recommendation: Kaufen from: 19.06.2025 Target price: €28 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu M1 Kliniken AG (ISIN:  [ … ]

M1 Kliniken AG: Strong Q1 2025 with 29% EBIT Growth and Earnings per Share of EUR 0.31 Berlin, 5 June 2025 – M1 Kliniken AG (ISIN: DE000A0STSQ8) has made a strong start to the 2025 financial year and continues its profitable growth trajectory. The significant improvement in earnings results from the consistent implementation of efficiency measures [ … ]

M1 Kliniken AG: Strong Earnings Growth in 2024 – Strategic Focus on Global Market Leadership Berlin, 21/05/2025 - M1 Kliniken AG (ISIN: DE000A0STSQ8) today published its annual report for the 2024 financial year. The M1 Group continued on its growth trajectory, driven in particular by the high-margin Beauty segment. Looking ahead, the company sees [ … ]

M1 Kliniken AG publishes preliminary figures for the 2024 financial year: Strong EBIT growth (+70%) and significant increase in earnings per share (+57%)  Berlin, April 29, 2025 - M1 Kliniken AG (ISIN: DE000A0STSQ8) has published its preliminary IFRS consolidated figures for the 2024 financial year. The Group once again recorded strong growth in i [ … ]

M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment HAEMATO AG, which is majority-owned by M1 Kliniken AG, has received a so-called Conditional Binding Offer (CBO) for the acquisition of its trading segment, the wholly-owned subsidiary HAEMATO PHARM GmbH. The Executive Board and Supervisory Board of HAEMATO AG are c [ … ]